Studies how people with advanced lung cancer are treated first
Reviews medical records of adults with advanced non-small cell lung cancer starting first treatment.
Plain-language title generated from the registry record
Registry title: DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns
Key facts
- Where
- Recife, Rio de Janeiro, Salvador, and São Paulo, BrazilSee the 4 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study includes adults with advanced non-small cell lung cancer that cannot be removed by surgery or has spread. They start first-line cancer treatment at a participating center in 2025 or 2026.
- Age
- Over 18 years old
- Sex
- All sexes can join
- Disease stage
- Advanced non-small cell lung carcinoma, unresectable or metastatic
- Earlier treatment
- Starting first-line cancer treatment at a participating center between January 2025 and January 2026
Main reasons for not taking part
- Localized disease that can be treated locally
- Non-epithelial tumor type
- Small cell carcinoma
- Neuroendocrine tumor
- Unresectable NSCLC treated with the PACIFIC protocol and now being followed up
Read by machine on 12 November 2026.
Where in Brazil
- RecifeHospital not named in the registryNo longer taking part
- Rio de JaneiroHospital not named in the registryTaking people
- SalvadorHospital not named in the registryTaking people
- São PauloHospital not named in the registryNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07109154
- Record updated
- 13 May 2026
- Original description
This is a prospective, observational, multicenter study, in which clinical and demographic data will be extracted from medical records. Convenience sample, with an estimated inclusion of 200 patients treated in seven participating centers.Read full original descriptionShow less
DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns Observational Study (Prospective and Survey); Evaluation Patterns of Choice in First Line Treatment of Metastatic NSCLC
This is a prospective, observational, multicenter study, in which clinical and demographic data will be extracted from medical records. Convenience sample, with an estimated inclusion of 200 patients treated in seven participating centers.
Eligible tumors for this project will be from patients with advanced (unresectable or metastatic) non-small cell lung carcinoma, who will start first-line oncological treatment in one of the participating centers between 2025 and 2026 (between January 2025 and January 2026). Patients must be over 18 years old and data must be available in electronic medical records.
Medical records will be assessed to confirm patients' eligibility. Patients with localized disease amenable to local treatment, non-epithelial histology, small cell carcinoma and neuroendocrine tumor will not be eligible.
A survey will be designed targeting thoracic and generalist medical oncologists, aiming to understand the factors guiding the choice of first-line treatment regimens and to compare these insights with real-world data. The survey will be directed to Brazil, with an estimated of 200 filled files.
Inclusion: Advanced (unresectable or metastatic) non-small cell lung carcinoma; First-line oncological treatment in one of the participating centers between 2025 and 2026 (between January 2025 and January 2026); > 18 years old; Data available in electronic medical records.
Exclusion: Patients with unresectable NSCLC who underwent treatment with the PACIFIC protocol and are being followed up; Localized disease amenable to local treatment; Non-epithelial histology; Small cell carcinoma; Neuroendocrine tumor.